All the news Showing 10 of 98 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study Liz Highleyman / 21 July 2016 The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well tolerated in the ASTRAL-5 trial, according ... Does having HIV affect response to hepatitis C treatment? Liz Highleyman / 16 May 2016 A study from the US Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that ... Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection Liz Highleyman / 19 April 2016 A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C co-infection, according to results ... Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV EASL press release / 13 April 2016 Starting HIV therapy associated with improvements in liver function, especially when viral load is suppressed Michael Carter / 21 March 2016 Starting antiretroviral therapy is associated with improvements in liver function in HIV-positive men with and without viral hepatitis co-infection, investigators from the United States report in the online edition of the Journal of ... Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals Liz Highleyman / 11 March 2016 Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for people with HIV and HCV co-infection, according to a study presented ... Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 ← Prev1...23456...10Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds